Collaborative on Countering the US Opioid Epidemic [8] has been focusing on comprehensive and collaborative efforts to fundamentally address the opioid epidemic crisis. All of these major initiatives emphasize pain education as a key component in the fight against the dual crises of chronic pain and the opioid epidemic. I am honored to represent the AAPM on the HHS Pain Management Task Force and the NAM Action Collaborative and contribute to these important initiatives of our nation on your behalf.

The AAPM emphasizes pain education as a strategic priority in its mission. In the coming years, we will focus on defining competencies and developing educational content for a spectrum of audiences, including patients, the public, and clinicians; further elevating the impact of our journal Pain Medicine; improving the educational programming of our annual meetings as long-standing cornerstones of the AAPM’s education efforts; and promoting integration of educational efforts by various stakeholders, including the NIH, HHS, and NAM. We will place special emphasis on pain fellowship education, as today’s fellows are tomorrow’s leaders. We will also expand our membership to doctoral-level professionals specializing in pain medicine, who will not only contribute to multidisciplinary patient care but also play a key role in our educational and research efforts. We will identify major barriers to effective pain education and explore better and more innovative ways to improve pain education. We will need to define outcome metrics to measure the success or failure of pain education efforts.

Pain medicine is a multidisciplinary specialty that has been constantly evolving and expanding in the last few decades and will continue to do so at accelerated rates. Pain education will inevitably evolve in terms of objectives, content, and delivery. But the purpose of pain education, to improve patient care, will never change.

Jianguo Cheng, MD, PhD, FIPP*,†
*American Academy of Pain Medicine, Chicago, Illinois;
†Cleveland Clinic, Cleveland, Ohio, USA

PERSPECTIVE & COMMENTARY

Pain Medicine 2019; 20: 429–433
doi: 10.1093/pm/pny228

Commentary

International Stakeholder Community of Pain Experts and Leaders Call for an Urgent Action on Forced Opioid Tapering

We, the undersigned, stand as a unified community of stakeholders and key opinion leaders deeply concerned about forced opioid tapering in patients receiving long-term prescription opioid therapy for chronic pain. This is a

large-scale humanitarian issue. Our specific concerns involve:

- rapid, forced opioid tapering among outpatients;
- mandated opioid tapers that require aggressive opioid dose reductions over a defined period, even when that period is an extended one.

Opioid tapering guidelines were created, in part, to decrease harm to patients resulting from high-dose opioid therapy for chronic pain. However, countless “legacy patients” with chronic pain who were progressively escalated to high opioid doses, often over many years, now face additional and very serious risks resulting from rapid tapering or related policies that mandate extreme dose reductions that are aggressive and unrealistic.

Rapid forced tapering can destabilize these patients, precipitating severe opioid withdrawal accompanied by worsening pain and profound loss of function. To escape the resultant suffering, some patients may seek relief from illicit (and inherently more dangerous) sources of opioids, whereas others may become acutely suicidal. Regardless of one’s view on the advisability of high-dose opioid therapy, every thoughtful clinician recognizes rapid tapering as a genuine threat to a large number of patients who are often medically complex and vulnerable. Indeed, even slower tapers should include realistic, patient-centered goals that are achievable and account for individual patient factors.

New and grave risks now exist because of forced opioid tapering: an alarming increase in reports of patient suffering and suicides within and outside of the Veterans Affairs Healthcare System in the United States. Reports suggest that forced tapering is also occurring in patients on opioid doses below the Centers for Disease Control and Prevention Opioid Guideline threshold of 90 morphine equivalent daily dose. These patients too are at risk of harm from overly aggressive tapering.

Patients on legacy opioid prescriptions require different considerations and careful attention to the methods by which opioid tapers might be considered and implemented. Currently, no data exist to support forced, community-based opioid tapering to drastically low levels without exposing patients to potentially life-threatening harms. Existing data that support rapid reductions of opioid doses—often to zero—were conducted in highly structured, supportive, interdisciplinary, inpatient settings or “detox” programs in which medications and other approaches were used to minimize the symptoms of withdrawal. These data do not inform community-based opioid tapering. Currently, nonsensical tapering policies are being enacted throughout the country without careful systems that attend to patient safety. The methods by which a taper is conducted matter greatly.

We therefore call for an urgent review of mandated opioid tapering policies for outpatients at every level of health care—including prescribing, pharmacy, and insurance policies—and across borders, to minimize the iatrogenic harm that ensues from aggressive opioid tapering policies and practices.

Almost 18 million Americans are currently taking long-term prescription opioids. We ask the Department of Health and Human Services to consider the following to mitigate harms in this special, at-risk population:

- Enact policies that prohibit or minimize rapid, forced opioid tapering in outpatients taking legacy opioid prescriptions (this includes prescribers and health care organizations, pharmacies, and insurance payors).
- Provide compassionate systems for opioid tapering, if indicated; that includes careful selection, patient-centered methods, close monitoring, triaging of adverse events, and realistic end-dose goals that are evidence-based and derived from applicable outpatient tapering data.
- Convene patient advisory boards at all levels of decision-making to ensure that patient-centered systems are developed and patient rights are protected within the context of pain care.
- Require inclusion of pain management specialists at every level of decision-making about future opioid policies and guidelines.

In standing as a unified community of concerned scientists, experts, citizens, and leaders of pain organizations in our respective countries, we call for the development and implementation of policies that are humane, compassionate, patient-centered, and evidence-based in order to minimize iatrogenic harms and protect patients taking long-term prescription opioids.
Darnall et al.

Boston, Massachusetts; Long School of Medicine, UT Health San Antonio, San Antonio, Texas; American Chronic Pain Association, Rocklin, California; Palliative & Supportive Care, Orlando UF Health Cancer Center, Orlando, Florida; Flamingo Pain Specialists, PLLC, Las Vegas, Nevada; International Pain Foundation; Arizona Pain Society; Program of Excellence in Addictions Research (Pain Self-Management/Opioid Use Disorder), Washington State University, Spokane, Washington; College of Nursing, Washington State University, Spokane, Washington; Palliative Care, University of Iowa College of Pharmacy, Iowa City, Iowa; Institute of Clinical Excellence, University of Florida, Gainesville, Florida; Albany College of Pharmacy and Health Sciences, Albany, New York; Western New England University College of Pharmacy, Springfield, Massachusetts; Advanced PACT Pain Clinic, Hampton VA Medical Center, Hampton, Virginia; VA New England Mental Illness, West Haven, Connecticut; Eastern Virginia Medical School, Norfolk, Virginia; Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut; Veteran of the United States Navy, Air Medical Physician’s Association, Medical Missions Outreach; Urban Recovery Center, Silver Hill Hospital, New Canaan, Connecticut; Chronic Pain and Recovery Center, Silver Hill Hospital, New Canaan, Connecticut; Critical Access Hospital Specialist in Hospice & Palliative Care, Cook Hospital & Care Center, Cook, Minnesota; Arachnoiditis Research Team, Texas Women’s University; Health Policy & Management, University of Southern California, Los Angeles, California; Northern California Association of Pain Psychologists; Door To Door Doctors, Milbridge, Maine; Diplomat in Clinical Social Work, Portland, Oregon; The Alliance for the Treatment for Intractable Pain; Arizona Pain and Spine, Mesa, Arizona; Central Pain Nerve Center; Department of Physical Therapy, Academy of Geriatric Physical Therapy, University of Miami Miller School of Medicine; White River Health Care, PC, Muncie, Indiana; School of Medicine, Indiana University, Indianapolis, Indiana; AIPM; NEIGlobal; AAPS; Yakima, Washington; Mission Viejo, California; Southern Behavioral Medicine Associates PLLC, Hattiesburg, Mississippi; Institute of Clinical Excellence, STAND The Haiti Project, Portland, Oregon; End of Life, Psychiatric and Mental Health Nurse, Long Term Care, Education, Alliance for the Treatment of Intractable Pain, Akron, Ohio; #360DxTx; The Butterfly Protocol; CALHN Pain Management Unit, Woodville, Adelaide, South Australia, Australia; Faculty of Pain Medicine, ANZCA; Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, Washington; Anesthesiology, Perioperative and Pain Medicine, Stanford University, Palo Alto, California; Public Health and Preventive Medicine, Monash University, Melbourne, Australia; Gateway Psychiatric Group, St. Louis, Missouri; The University of Alabama, Tuscaloosa, Alabama; Department of Public Health & Community Medicine, Boston Pain Care, Tufts University School of Medicine, Boston, Massachusetts; AiHM, Private Medical Practice, Las Vegas, Nevada; Nevada Docs Care LLC, Las Vegas, Nevada; CAW360 Network; Virginia Health Psychology; Division of General Pediatrics, Grayken Center for Addiction, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts; Pain Section, James A Haley Veterans’ Hospital, Tampa, Florida; Department of Psychology, Wayne State University, Detroit, Michigan; Fort Myers, Florida; Stanford Pain Management Center; Christus St. Vincent, Acute Pain Service; Reflex Sympathetic Dystrophy Syndrome Association; Pro-Activity; Stanford University School of Medicine, Department of Anesthesiology, Perioperative, and Pain Medicine, Palo Alto, California; Oklahoma City, Oklahoma; Department of Anesthesiology, Perioperative, and Pain Medicine, Palo Alto, California; Clinical Department of Family & Community Medicine, UT Health, San Antonio, San Antonio, Texas; Division of Behavioral Medicine, Department of Psychiatry, UT Health, San Antonio, San Antonio, Texas; Mental Health- Private Practice, Alliance for the Treatment of Intractable Pain, Huntington, West Virginia; Department of Pharmacy Practice and Science, University of Iowa College of Pharmacy, Iowa City, Iowa; Anesthesiology & Pain Management, Interventional Pain Medicine, Cahaba Pain & Spine Care, Hoover, Alabama; Central Adelaide Local Health Network, Australian Pain Society; Massachusetts Pain Initiative Legislative Council Leadership Advisory Group, ABMS ABA Diplomat in Anesthesiology and Pain Medicine, Newton Center, Massachusetts;